
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. is strategically positioned within the biopharmaceutical sector, focusing on metabolic and endocrine disorders, with a robust clinical program pipeline that includes promising products like VK2809 and VK0214. The increasing interest in independent, late-stage metabolic players in the industry, combined with Viking's advanced maturity and data strength, enhances the company's appeal for potential partnerships and financing opportunities. Furthermore, key clinical updates and a focus on new products such as VK2735, which offers a potentially advantageous monthly dosing regimen, are expected to bolster investor sentiment ahead of significant clinical milestones.
Bears say
Viking Therapeutics Inc. is facing significant industry-standard risks, including potential unexpected outcomes from clinical trials and regulatory uncertainties that could adversely affect its pipeline of metabolic and endocrine disorder treatments. Additionally, the company operates in increasingly complex and price-sensitive commercial markets, which may impact the viability and profitability of its product candidates such as VK2809, VK5211, and VK0214. Heightened scrutiny of licensing deals, particularly in the context of US/China relations, further complicates the company's strategic position and may contribute to a challenging operating environment.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares